Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.560 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2026 Add to My Watchlist

Price and Volume

Volume	2,295
Open	2.560
Bid (Size)	2.500 (100)
Ask (Size)	2.780 (200)
Prev. Close	2.560
Today's Range	2.560 - 2.560
52wk Range	2.120 - 115.50
Shares Outstanding	171,350,166
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

June 23, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

June 23, 2026

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Performance

YTD	-92.7%	-92.7%
1 Month	-17.7%	-17.7%
3 Month	-81.6%	-81.6%
6 Month	-93.3%	-93.3%
1 Year	-97.3%	-97.3%

More News

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

June 22, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Compliant with Nasdaq Bid Price Rule

May 27, 2026

Via ACCESS Newswire

Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News ↗

May 20, 2026

Via Chartmill

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

June 18, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

June 12, 2026

Via ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

June 08, 2026

Via ACCESS Newswire

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

May 28, 2026

Via ACCESS Newswire

Jaguar Health (JAGX) Q3 2025 Earnings Transcript ↗

May 21, 2026

Via The Motley Fool

Wondering what's happening in today's after-hours session? ↗

May 20, 2026

Via Chartmill

Jaguar Health Reports First Quarter 2026 Financials

May 20, 2026

Via ACCESS Newswire

Jaguar (JAGX) Q4 2025 Earnings Transcript ↗

May 20, 2026

Via The Motley Fool

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

May 19, 2026

Via ACCESS Newswire

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

May 08, 2026

Via ACCESS Newswire

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

May 06, 2026

Via ACCESS Newswire

These stocks are moving in today's session ↗

May 04, 2026

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

May 04, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Monday's session. ↗

May 04, 2026

Via Chartmill

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

May 04, 2026

Via ACCESS Newswire

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

April 29, 2026

Via ACCESS Newswire

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

April 27, 2026

Via ACCESS Newswire

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

April 24, 2026

Via ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

April 20, 2026

Via ACCESS Newswire

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

April 13, 2026

Via ACCESS Newswire

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?

Yes, Jaguar Health, Inc. - Common Stock is publicly traded.

What exchange does Jaguar Health, Inc. - Common Stock trade on?

Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jaguar Health, Inc. - Common Stock?

The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market

What is the current price of Jaguar Health, Inc. - Common Stock?

The current price of Jaguar Health, Inc. - Common Stock is 2.560

When was Jaguar Health, Inc. - Common Stock last traded?

The last trade of Jaguar Health, Inc. - Common Stock was at 06/23/26 04:00 PM ET

What is the market capitalization of Jaguar Health, Inc. - Common Stock?

The market capitalization of Jaguar Health, Inc. - Common Stock is 438.66M

How many shares of Jaguar Health, Inc. - Common Stock are outstanding?

Jaguar Health, Inc. - Common Stock has 439M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.